These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 30467370)

  • 21. Association between Individual versus Community-level Social Vulnerability and Neonatal Opioid Withdrawal Syndrome among Pregnant Individuals Receiving Buprenorphine for Opioid Use Disorder.
    Mason I; Abdelwahab M; Stiles A; Wu J; Venkatesh KK; Rood KM
    Am J Perinatol; 2024 May; 41(S 01):e3157-e3163. PubMed ID: 37890511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Racial and Ethnic Disparities in Maternal and Infant Outcomes Among Opioid-Exposed Mother-Infant Dyads in Massachusetts (2017-2019).
    Peeler M; Gupta M; Melvin P; Bryant AS; Diop H; Iverson R; Callaghan K; Wachman EM; Singh R; Houghton M; Greenfield SF; Schiff DM
    Am J Public Health; 2020 Dec; 110(12):1828-1836. PubMed ID: 33058701
    [No Abstract]   [Full Text] [Related]  

  • 23. The effect of prenatal alcohol co-exposure on neonatal abstinence syndrome in infants born to mothers in opioid maintenance treatment.
    Kreitinger C; Gutierrez H; Hamidovic A; Schmitt C; Sarangarm P; Rayburn WF; Leeman L; Bakhireva LN
    J Matern Fetal Neonatal Med; 2016 Mar; 29(5):783-8. PubMed ID: 25758627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neonatal Outcomes after Medications for Opioid Use Disorder during Pregnancy in a State Women's Prison Facility, 2016-2019.
    Knittel AK; Swartzwelder RA; Zarnick S; Tsujimoto TM; Horne T; Lin FC; Edwards J; Amos E; Alexander J; Thorp J; Jones HE
    J Addict Med; 2023 Sep-Oct 01; 17(5):587-591. PubMed ID: 37788614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Care-by-parent model as a tool for reduction of neonatal opioid withdrawal syndrome in neonates exposed to buprenorphine maintenance therapy in-utero.
    Lawlor ML; Shook LA; McQuerry K; Srinivasan A; Johnson QB; Chavan NR; Critchfield AS
    J Matern Fetal Neonatal Med; 2020 Aug; 33(16):2718-2722. PubMed ID: 30563376
    [No Abstract]   [Full Text] [Related]  

  • 26. Autonomous Care Pathway to Patient Opioid Abstinence: Should All Programs Offer this Approach?
    Patel A; Dietz P; Casto A; DePond J; Taylor L; Seybold D; Blake A; Calhoun B
    Issues Law Med; 2021; 36(2):193-210. PubMed ID: 36629776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding barriers to timely identification of infants at risk of neonatal opiate withdrawal syndrome.
    Howell MP; Smith AM; Lindsay EB; Drury SS
    J Matern Fetal Neonatal Med; 2021 Apr; 34(7):1161-1166. PubMed ID: 31195865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variations in Infant CYP2B6 Genotype Associated with the Need for Pharmacological Treatment for Neonatal Abstinence Syndrome in Infants of Methadone-Maintained Opioid-Dependent Mothers.
    Mactier H; McLaughlin P; Gillis C; Osselton MD
    Am J Perinatol; 2017 Jul; 34(9):918-921. PubMed ID: 28320034
    [No Abstract]   [Full Text] [Related]  

  • 29. Assessing the Impact of Prenatal Medication for Opioid Use Disorder on Discharge Home With Parents Among Infants With Neonatal Opioid Withdrawal Syndrome.
    Singleton R; Rutz S; Day G; Hammes M; Wilson AS; Herrick M; Mazut C; Brunner L; Prince J; Desnoyers C; Shaw J; Hirschfeld M; Palis H; Slaunwhite A
    J Addict Med; 2022 Nov-Dec 01; 16(6):e366-e373. PubMed ID: 35245916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severity of neonatal opioid withdrawal syndrome with prenatal exposure to serotonin reuptake inhibitors.
    Bakhireva LN; Sparks A; Herman M; Hund L; Ashley M; Salisbury A
    Pediatr Res; 2022 Mar; 91(4):867-873. PubMed ID: 34588611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome.
    Jones HE; Kraft WK
    Clin Perinatol; 2019 Jun; 46(2):349-366. PubMed ID: 31010564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach. Part II: The clinical application of nonpharmacologic care for NAS/NOWS.
    Velez ML; Jordan C; Jansson LM
    Neurotoxicol Teratol; 2021; 88():107032. PubMed ID: 34600100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine and methadone for opioid addiction during pregnancy.
    Mozurkewich EL; Rayburn WF
    Obstet Gynecol Clin North Am; 2014 Jun; 41(2):241-53. PubMed ID: 24845488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach.
    Velez ML; Jordan CJ; Jansson LM
    Neurotoxicol Teratol; 2021; 88():107020. PubMed ID: 34419619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obstetrical and neonatal outcomes of methadone-maintained pregnant women: a canadian multisite cohort study.
    Ordean A; Kahan M; Graves L; Abrahams R; Kim T
    J Obstet Gynaecol Can; 2015 Mar; 37(3):252-257. PubMed ID: 26001872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opioid dependence and pregnancy: minimizing stress on the fetal brain.
    McCarthy JJ; Leamon MH; Finnegan LP; Fassbender C
    Am J Obstet Gynecol; 2017 Mar; 216(3):226-231. PubMed ID: 27729254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT (NASCENT) program: protocol for a stepped wedge cluster randomized trial of a hospital-level Neonatal Abstinence Syndrome rooming-in intervention.
    Wine O; McNeil D; Kromm SK; Foss K; Caine V; Clarke D; Day N; Johnson DW; Rittenbach K; Wood S; Hicks M
    BMC Health Serv Res; 2023 May; 23(1):448. PubMed ID: 37149626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between prenatal opioid exposure, neonatal opioid withdrawal syndrome, and neurodevelopmental and behavioral outcomes at 5-8 months of age.
    Bakhireva LN; Holbrook BD; Shrestha S; Leyva Y; Ashley M; Cano S; Lowe J; Stephen JM; Leeman L
    Early Hum Dev; 2019 Jan; 128():69-76. PubMed ID: 30554024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway.
    Nechanská B; Mravčík V; Skurtveit S; Lund IO; Gabrhelík R; Engeland A; Handal M
    Addiction; 2018 Jul; 113(7):1286-1294. PubMed ID: 29443414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care.
    Pryor JR; Maalouf FI; Krans EE; Schumacher RE; Cooper WO; Patrick SW
    Arch Dis Child Fetal Neonatal Ed; 2017 Mar; 102(2):F183-F187. PubMed ID: 28073819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.